Why The Pulmonx LUNG Narrative Is Shifting After Target Cut And Leadership Return [Yahoo! Finance]
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: Yahoo! Finance
share, with the discount rate and revenue growth assumption adjusted only slightly. That mix of a trimmed target on the one hand and largely steady long term inputs on the other reflects how analysts are trying to balance renewed attention on leadership changes, the clinical track record of Zephyr valves, and the risks around execution. As you read on, keep an eye on how these moving pieces shape the story so you can decide how you want to track shifts in the Pulmonx narrative over time. Stay updated as the Fair Value for Pulmonx shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Pulmonx. ?? Bullish Takeaways Lake Street keeps a Buy rating on Pulmonx even after trimming its price target to US$4 from US$8, signaling that the firm still sees the shares as appealing at recent trading levels. The analyst points to what they describe as "vast clinical verification/proof of concept of Zephyr valves" as a core sup
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx (NASDAQ:LUNG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 [Yahoo! Finance]Yahoo! Finance
- Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026GlobeNewswire
- How Leadership Changes And Analyst Revisions Are Shaping Pulmonx's Valuation Story [Yahoo! Finance]Yahoo! Finance
- What New Catalysts Are Shifting the Pulmonx Story for Investors [Yahoo! Finance]Yahoo! Finance
LUNG
Earnings
- 11/12/25 - Beat
LUNG
Sec Filings
- 1/22/26 - Form 144
- 1/15/26 - Form 144
- 1/14/26 - Form 144
- LUNG's page on the SEC website